Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Tim Illidge"'
Autor:
Swaminathan Iyer, Deepa Jagadeesh, Eva Domingo Domènech, Fabio Benedetti, Antonia Rodriguez Izquierdo, Kamal Bouabdallah, Umberto Vitolo, Tim Illidge, Jingmin Liu, Scott Knowles, Steven Horwitz
Publikováno v:
HemaSphere, Vol 7, p e4008899 (2023)
Externí odkaz:
https://doaj.org/article/d5ef10a1ddf34c76b35a71343049b14f
Autor:
Jamie Frankish, Debayan Mukherjee, Erminia Romano, Katharina Billian-Frey, Matthias Schröder, Karl Heinonen, Christian Merz, Mauricio Redondo Müller, Christian Gieffers, Oliver Hill, Meinolf Thiemann, Jamie Honeychurch, Tim Illidge, Jaromir Sykora
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionThe ability to modulate and enhance the anti-tumor immune responses is critical in developing novel therapies in cancer. The Tumor Necrosis Factor (TNF) Receptor Super Family (TNFRSF) are potentially excellent targets for modulation which
Externí odkaz:
https://doaj.org/article/3a2c8f98856e4fc4a7c38804f359c93f
Autor:
Vicky Smith, Debayan Mukherjee, Sapna Lunj, Ananya Choudhury, Peter Hoskin, Catharine West, Tim Illidge
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Introduction Recent data has demonstrated that hypoxia drives an immunosuppressive tumour microenvironment (TME) via various mechanisms including hypoxia inducible factor (HIF)-dependent upregulation of programmed death ligand 1 (PD-L1). Bot
Externí odkaz:
https://doaj.org/article/5a3b699691944cdba47478b8e3d7583a
Autor:
John Radford, Toyin Adedayo, Arzhang Ardavan, Sally F. Barrington, Leanne Berkahn, Stephane Chauvie, Laura Clifton-Hadley, Graham P. Collins, Michael Crump, David Cutter, Darren Edwards, Martin Hutchings, Tim Illidge, Amy A. Kirkwood, Kim Linton, Craig H. Moskowitz, Pip Patrick, Beth Phillips, Lois Shepherd, Sanne Tonino, Judith Trotman, Joanna Williams, Nicole Wong Doo
Publikováno v:
HemaSphere, Vol 6, Pp 12-13 (2022)
Externí odkaz:
https://doaj.org/article/d506da6863614fcc9905cf968405f6fe
Autor:
Udo S Gaipl, Dmitriy Zamarin, Felipe Prosper, Francesco M Marincola, Alessandra Cesano, Howard L Kaufman, Laurence Zitvogel, Tim Illidge, Taha Merghoub, Sandra Demaria, Abhishek D Garg, Patrizia Agostinis, James W Hodge, George Coukos, Akseli Hemminki, Öystein Rekdal, Jian Han, John Stagg, Sarah Warren, Lorenzo Galluzzi, Dobrin Draganov, Silvia C Formenti, Mark J Smyth, Radek Špíšek, Michael T Lotze, Takahiro Yamazaki, Guido Kroemer, Daolin Tang, Eric Deutsch, Jitka Fucikova, Sofia R Gameiro, Ilio Vitale, Sandy Adjemian, Aitziber Buqué Martinez, Timothy A Chan, Richard L Edelson, Lucia Gabriele, Encouse Golden, Kevin J Harrington, Dewan Md Sakib Hossain, Michael Karin, Oliver Kepp, Juan Jose Lasarte, Sherene Loi, Gwenola Manic, Alan A Melcher, Karen L Mossman, Maria Rescigno, Chiara Riganti, Antonella Sistigu, Bryan E Strauss, Kazuki Tatsuno, Stefaan W van Gool, Peter Vandenabeele
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular and microenviro
Externí odkaz:
https://doaj.org/article/a9d90895f1e544d9989ad2cde51f79c0
Publikováno v:
Haematologica, Vol 98, Iss 4 (2013)
The CD30-targeted agent brentuximab vedotin has shown impressive activity in relapsed/refractory Hodgkin lymphoma and anaplastic large cell lymphoma in phase II studies. We have treated 24 patients with relapsed/refratory disease enrolled onto a Name
Externí odkaz:
https://doaj.org/article/5737307485ae426fb306d7e8912f0c48
Autor:
James M. Price, Hitesh B. Mistry, Guy Betts, Eleanor J. Cheadle, Lynne Dixon, Kate Garcez, Tim Illidge, Zsuzsanna Iyizoba-Ebozue, Lip Wai Lee, Andrew McPartlin, Robin J.D. Prestwich, Savvas Papageorgiou, Dylan J. Pritchard, Andrew Sykes, Catharine M. West, David J. Thomson
Publikováno v:
Journal of Clinical Oncology. 40:2203-2212
PURPOSE There is a need to refine the selection of patients with oropharyngeal squamous cell carcinoma (OPSCC) for treatment de-escalation. We investigated whether pretreatment absolute lymphocyte count (ALC) predicted overall survival (OS) benefit f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1fcf6507099dccee6ad30bab1390c42
https://doi.org/10.1200/jco.21.01991
https://doi.org/10.1200/jco.21.01991
Supplementary Figure 3 from Microscopic Intratumoral Dosimetry of Radiolabeled Antibodies Is a Critical Determinant of Successful Radioimmunotherapy in B-Cell Lymphoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48594c0e6cefd1caadd29f7724f9fc45
https://doi.org/10.1158/0008-5472.22366286.v1
https://doi.org/10.1158/0008-5472.22366286.v1
Supplementary Figure 1 from Microscopic Intratumoral Dosimetry of Radiolabeled Antibodies Is a Critical Determinant of Successful Radioimmunotherapy in B-Cell Lymphoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b9e82ff2f1c01432a8970cee9ff16c4
https://doi.org/10.1158/0008-5472.22366292.v1
https://doi.org/10.1158/0008-5472.22366292.v1
Radioimmunotherapy is a highly effective treatment for some hematologic malignancies; however, the underlying mechanisms of tumor clearance remain poorly understood. We have previously shown that both targeted radiation using 131I-labeled anti–MHC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf7e9b876f295b2534da2c0c40364297
https://doi.org/10.1158/0008-5472.c.6495077.v1
https://doi.org/10.1158/0008-5472.c.6495077.v1